Kornimate/medical-research-clean huggingface dataset:
the added value of a mobile application of community case management on pediatric referral rates in malawi

Conditions: Infectious Diseases

Summary: community case management (ccm) is a clinical decision aid used by frontline health surveillance assistants (hsas) in malawi to manage uncomplicated cases of pneumonia and malaria (amongst other conditions). children identified has having complicated illness are urgently referred to larger health facilities better equipped to clinically manage these more complex presentations. there is evidence to suggest hsas are missing opportunities to refer seriously ill children, and parents/caregivers are failing to comply with urgent referral recommendations when given; reducing the overall effectiveness of the ccm strategy. use of mobile technology for deploying ccm has been demonstrated in prior research as feasible to evaluate, acceptable to health workers and parents/caregivers and improving health worker fidelity to the guidelines, but it is unknown if this translates into increased referral and referral completion rates. this trial seeks to evaluate the added value of a purpose developed mobile solution for ccm, called supporting life electronic community case management (sl eccm app) on hsa referral and parent/caregiver health seeking behavior.


Eligibility criteria:
inclusion criteria: * parents/caregivers aged ≥18 years with spoken fluency in chichewa, tonga and tumbuka * children aged ≥2 months to \<5 years * able/willing to give voluntary verbal consent exclusion criteria: * parents/caregivers aged \<18 years * children aged \<2 months or ≥5 years * children who are convulsing or unconscious/unresponsive at presentation * parents/caregivers unable/unwilling to give voluntary verbal consent
early physical therapy in patients with sepsis

Conditions: SEPTIC SHOCK; SEPSIS SYNDROME; Multiple Organ Dysfunction Syndrome

Summary: it is clearly shown that patients in the intensive care unit (icu) with severe sepsis or multi organic failure are very susceptible to develop neuromuscular complications. that can be attributed to a hyper catabolic state, general inflammation and immobilization. this can leads a significant muscle wasting, polyneuropathy and/or myopathy. these alterations have been defined with the term intensive care acquired weakness (icuaw) and can leads important functional squeals and impaired quality of life for months, years and in some cases irreversibly. to overcome these complications, early activation by physiotherapy becomes an important tool. this type of treatment has been show to be feasible, safe and improves the functional capacity of patients. in addition to a reduction in the duration of icu and hospital stay and improved quality of life for patients. the objective of this study is to demonstrate that the early and active physical activity in patients with severe sepsis can limit the loss of muscle mass and complications related to this type of damage. procedures: patients or relatives will be asked to participate in the study. if a positive response is done, patients will be randomized in an intervention or control group. a baseline evaluation will be performed during the first day of study admission. that includes a physical exploration, electrophysiological studies, skeletal muscle histological/biochemical evaluations and monitoring of blood biomarkers and others clinical outcomes will be registered. intervention will be divided in a morning and afternoon times, patient will be positioned in chair or bed and mobilized by physiotherapist. as usual, all patients will be attaining manual mobilization for 20 minutes twice a day. only for intervention group, additional cycle-ergometer exercise will be performed for 30 minutes at better performance achieved and tolerated for patient. all vitals parameters will be strictly controlled before, during and after intervention. the same baseline evaluation will be repeated after day 7 and clinical outcomes will be registered until icu discharge.


Eligibility criteria:
inclusion criteria: * hemodynamically stable patients. * admitted to icu for sepsis or mof (multiple organ failure) or who developing during their icu stay within the first 24 hours of the icu admission. * with an expected icu stay of at least 7 days. exclusion criteria: * patients without approved consent. * patients with a known neuromuscular disorder before icu admission. * moribund patients. * severe metabolic/hemodynamic instability despite pharmacological support. * having conditions that impair evaluation techniques or intervention methods.

Keywords: sepsis
value of platelet-rich plasma in post severe acute respiratory syndrome coronavirus 2

Conditions: Anosmia

Summary: the study will be conducted to evaluate : the efficacy of platelet rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (sars-cov-2) via the growth factors involved in accelerating and enhancing healing.

smell is essential sensory function for good quality of life as its preservation helps in identifying several harmful odors . viral urtis can lead to olfactory disorders of varying degree and duration 70% of urti caused by rhinovirus, adenovirus ,influenza and parainfluanza virus smell disorders are divided into two types quantitative (anosmia and hyposmia) qualitative (parosmia and phantosmia) anosmia is a total loss of smell . hyposmia is a decrease in the sense of smell. parosmia is a distortion of the smell in presence of an existing stimulus . phantosmia (cacosmia) is distortion of the smell in absence of an existing stimulus severe acute respiratory syndrome coronavirus2 (sars-cov-2)which is a global pandemic started in china 2019 one of respiratory tract infection that affect olfaction and cause varying types of smell impairment. smell disorders seem to be more common in sars-cov2 than other respiratory infections as in some patient persist for long time after resolution of respiratory symptoms current evidence suggest that olfactory impairment results from propensity of sars-cov2 for neuroinvasion and neurotrophic activities . majority of patients experience some level of smell impairment most often temporary as olfactory neuroepithelium has regenerative power . european study published on 16 july 2020 reported that some patient affected by sars -cov2 come solely with olfactory symptoms and most of patient recovered within 2 weeks ,smell not recovered in one quarter of patient 15 once olfactory dysfunction persists more than 2 weeks a therapy should be considered to avoid persistent impairment of smell one of therapies can be used in ttt of smell disorders ( platelet _rich plasma) prp is a process in which a small amount of blood from test subject is separated by special centrifugation process. prp contains many growth factor which have a neuroregenerative feature as well as therapeutic effect

Eligibility criteria:
inclusion criteria: 1. patient age above 18 who suffer from anosmia post severe acute respiratory syndrome coronavirus 2 (sars-cov-2 more than two weeks 2. normal airway passage 3. ct nose and para nasal sinuses does not show any nasal lesion exclusion criteria: 1. lesions obstruct airway as nasal polyps, tumors, chronic sinusitis and severe nasal septum deviation 2. previous sino nasal surgery 3. atrophic rhinitis 4. diabetic patients and those with medical history of bleeding disorders 5. recieving any medication affect platelets or bone marrow function for 2 weeks prior to testing
non-interventional study of indian patients with advanced renal cell cancer receiving therapy with sutent

Conditions: Renal Cell Carcinoma

Summary: the sutent® observational study is being proposed to assess the real-world usage patterns and effectiveness and tolerability of treatment of indian patients with advanced renal cell cancer with sutent®. generation of such information is expected to aid everyday clinical decision-making by indian doctors and will add to the body of generalizable evidence.

the assignment of the patient to sutent® treatment is not decided in advance by this noninterventional study protocol, but falls within current practice. the decision to prescribe sutent® is clearly not driven by the decision to include the patient in this study.the sample size for this study is not based on statistical considerations. it is expected that a minimum of 100 patients will be enrolled in the study by the end of the first year and the data collected would be adequate to fulfill the observational objectives of the study.the study will be initiated at 10 sites across india during the 1st year. the study may be expanded with the addition of new sites during the 2nd year.

Eligibility criteria:
inclusion criteria: * patients with advanced renal cell cancer * treatment naïve or cytokine refractory exclusion criteria: * patients presenting with a known hypersensitivity to sunitinib or its metabolites

Keywords: advanced renal cell cancer non interventional study renal cancer sutent metastatic advanced renal cell carcinoma
females with severe or moderate hemophilia a or b: a multi-center study

Conditions: Hemophilia A; Hemophilia B

Summary: to collect and analyze data on females with hemophilia so as to better define the difference between the study population and the male population with hemophilia.

this study is designed as an epidemiological study with retrospective clinical and genetic data collection and prospective quality of life (qol) data collections and genotyping of subjects without current molecular diagnosis. data on the genetic/chromosomal etiology of the condition will be collected through chart review. for those subjects who have not had molecular or cytogenetic analysis, molecular and cytogenetic testing will be offered after genetic counseling. those subjects who agree to have genetic testing will have 5-10 ml of blood drawn and sent to the cytogenetic laboratory at weill cornell medical college for testing to determine the chromosomal complement, and 5 ml of blood sent to dr. arupa ganguly at the university of pennsylvania for the identification of a factor viii or factor ix mutation, and x-chromosome inactivation studies.

Eligibility criteria:
inclusion criteria: * females with severe (fviii\<0.01u/dl) or moderate (fviii-0.01\<0.06 u/dl) hemophilia a * females with severe (fix\<0.01u/dl) or moderate (fix-0.01\<0.06u/dl) hemophilia b * willingness to participate in the study. exclusion criteria: * subjects who do not meet the inclusion criteria with respect to gender or hemophilia severity.
real world evidence of the effectiveness of paritaprevir/r - ombitasvir, ± dasabuvir, ± ribavirin in patients with chronic hepatitis c - an observational study in germany (life-c)

Conditions: Chronic Hepatitis C

Summary: the interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (abbvie regimen) ± ribavirin (rbv) for the treatment of chronic hepatitis c (chc) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. this observational study is the first effectiveness research examining the abbvie regimen ± rbv, used according to local label, under real world conditions in germany in a clinical practice patient population.


Eligibility criteria:
inclusion criteria: * treatment-naïve or -experienced patients with confirmed chc, genotype 1 or 4, receiving combination therapy with the interferon-free abbvie regimen ± rbv according to standard of care and in line with local label. * if rbv is co-administered with the abbvie regimen, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) * patients must voluntarily sign and date a patient authorization to use and/or disclose his/her pseudonymized health data prior to inclusion into the study * patient must not be participating or intending to participate in a concurrent interventional therapeutic trial exclusion criteria: • adolescents; people not treated according to label

Keywords: chronic hepatitis c dasabuvir ombitasvir+paritaprevir+ritonavir observational study quality of life work-ability fibrosis cirrhosis
detection of occult paroxysmal atrial fibrillation after stroke using prolonged ambulatory cardiac monitoring

Conditions: Stroke; Atrial Fibrillation

Summary: about one-third of patients with stroke have no documented cause for the cerebrovascular event (known as cryptogenic strokes). atrial fibrillation is a common cause of stroke, but when transient (paroxysmal) it may remain undiagnosed. recent data suggest that occult paroxysmal atrial fibrillation may be identified in patients with cryptogenic strokes using prolonged ambulatory cardiac rhythm monitors. the investigators designed this study pursuing the following goals: 1. to determine the prevalence of occult paroxysmal atrial fibrillation in patients with cryptogenic stroke using long-term mobile cardiac outpatient telemetry. 2. to compare this prevalence to that found in a control group with stroke of known, non-cardioembolic cause. 3. to look for clinical, laboratory, echocardiographic, and imaging data that serve as risk factors for occult paroxysmal atrial fibrillation in patients with cryptogenic stroke. 4. to examine the utility of mobile cardiac outpatient telemetry, a relatively new diagnostic tool, in the evaluation of patients with cryptogenic stroke.


Eligibility criteria:
inclusion criteria: * stroke or tia within previous 3 months * stroke work up including: ekg, serum lipids, serum tsh, tte or tee, brain ct and/or mri, vascular evaluation of head and neck using any combination of ultrasound, mra, cta, and conventional angiography exclusion criteria: * documented history of atrial fibrillation or flutter * pfo closure planned before conclusion of the monitoring period * incomplete stroke work up

Keywords: stroke atrial fibrillation
a multicenter collaborative study on the clinical features, expression profiling, and quality of life of infantile onset fshd

Conditions: Facioscapulohumeral Muscular Dystrophy

Summary: this study is an observational study that aims to advance our knowledge on infantile onset fshd. the study will include 50 participants of all ages who have presented with symptoms of fshd between birth and 10 years of age. study participation will involve a single day of assessments at one of the participating cinrg centers (to include physical exam, cognitive testing, eye exam, hearing test, strength testing and speech evaluations). the procedures may be split over additional days for scheduling purposes.


Eligibility criteria:
inclusion criteria: affected participants must have a clinical diagnosis of fshd, including the presence of all of the following features based on review of medical records and/or direct examination: * onset of symptoms involving the facial or shoulder girdle muscles * autosomal dominant inheritance in familial cases * contraction of the d4z4 repeat array from 1-10 (10 - 38 kb) copies in the 4q35 subtelomeric region, based on established molecular genetic techniques exclusion criteria: * symptomatic cardiomyopathy or severe cardiac arrhythmia which may limit the ability to complete the study protocol * maternal/mitochondrial mode of inheritance * evidence of an alternative diagnosis based on muscle biopsy or other available investigations
safety and pharmacokinetics (pk) study of single ascending doses of cvt-427 (zolmitriptan inhalation powder) in healthy adults

Conditions: Migraine

Summary: this study is the first study in humans with cvt-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and pk of single ascending doses of cvt-427 in adult healthy volunteers.

objectives: * to evaluate the overall safety and tolerability of single, inhaled doses of cvt-427 (zolmitriptan inhalation powder) in healthy adults, with special emphasis on cardiopulmonary effects. * to describe the pharmacokinetics (pk) of single, inhaled doses of cvt-427, zomig® tablet, and zomig® nasal spray in healthy adults.

Eligibility criteria:
inclusion criteria: * healthy adult men or women volunteers aged 18 to 65 years, inclusive; * triptan-naïve; * body mass index (bmi) between 18 to 30 kg/m2; * forced expiratory volume in one second (fev1) greater than 80% of predicted for race, age, sex, and height and fev1/fvc (forced vital capacity) ratio greater than or equal to 70%; * no history of asthma; * non-smoking for at least 5 years; * in good general health with no clinically significant abnormalities or recognized cardiovascular risk factors that preclude use of triptans and that would interfere with participation in this study as determined by medical history, physical examination, electrocardiogram, and clinical laboratory test results; and negative tests for drug and alcohol, serology, and for pregnancy for female subjects of childbearing potential. exclusion criteria: * subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and who does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product; * any cardiovascular risk factor including clinically relevant ecg parameter (e.g., pr interval, qrs deviation) or other clinically significant ecg abnormality; * history of asthma (including exercise-induced asthma and cold-induced asthma) or chronic obstructive pulmonary disorder (copd) requiring intermittent or continuous use of any oral or inhaled medication therapy within last 3 years; * any flu-like syndrome or other respiratory infections within 4 weeks of cvt-427 administration; * unable to tolerate blood draws.

Keywords: migraine attacks
high supracostal versus subcostal puncture in adult pcnl

Conditions: Urolithiasis

Summary: as the supra eleventh puncture pcnl is not well investigated in the literature we will conduct that randomised trial in comparison to the subcostal one

the use of percutaneous nephrolithotomy (pcnl) was first reported by fernström and johansson in 1976. percutaneous nephrolithotomy (pcnl) is the accepted treatment for staghorn stones, large renal stones, and some upper ureteric stones. achieving suitable access to the appropriate calyx is one of the most important steps during the pcnl procedure. effective puncture is key for the success of pcnl. an ideal percutaneous nephrolithotomy (pcnl) puncture has been described as one that provides the shortest and straightest access to all calculi, avoids major vessels, bowel and lung, lies along the axis of the calyx and causes minimal parenchymal damage. many studies have reported that supracostal access for pcnl is advantageous over infracostal access. by creating a straight path along the kidney's long axis, the upper-pole method guarantees access to the majority of the collecting system and makes it simpler to manipulate the rigid nephroscope and other rigid devices. therefore, supracostal puncture is perhaps the greatest method for gaining access to the upper pole calyx, where staghorn and big, complicated renal stones are most likely to be located. although pneumothorax, hydrothorax, and lung damage (1-10%) can result after a supracostal puncture, this injury can now be handled with minimal morbidity thanks to advances in surgical technique and understanding of pleural and diaphragmatic architecture.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * patients amenable for pcnl with stone burden between 2 cm - 4 cm (guy score 1-2-3) exclusion criteria: * ectopic kidney. * single middle calyceal stone. * skeletal anomalies. * bleeding diathesis. * active urinary tract infection. * patient refusing participation. * patients with active pulmonary and pleural disease.
efficacy of ketoprofen before hysterosalpingography

Conditions: Pain Relief

Summary: hysterosalpingography can cause pain and discomfort in several ways: use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the cannula; and injection of the dye


Eligibility criteria:
inclusion criteria: * any patient came for hysterosalpingography exclusion criteria: * any patient has contraindication to hysterosalpingography
gaze and stair walking in patients with vestibular dysfunction

Conditions: Vestibular Diseases

Summary: the aim of this study is to assess the differences in gaze and gait during the stair and ramp negotiation (+transition to normal level walking) between healthy controls and vestibular patients (fallers and non-fallers).

for a better understanding of falls in patients with vestibular disorders it might be important to identify the challenging environmental that provoke functional deficits; e.g. stair or ramp negotiation. the three steps at the ground and at the top of stairs is the most common location for missteps and stair accidents. this is supported by the observation made in a 12-month prospective study were 32% of the falls happened during the last step going down stairs in vestibular patients. it remains open if patient's vestibular dysfunctions have a different gaze or gait behavior than healthy individuals.

Eligibility criteria:
inclusion criteria: * all included patients are diagnosed with single or two-sided vestibular dysfunction. * adult male and female participant's (≥18 years) * signed informed consent after being informed exclusion criteria: * benign paroxysmal positional vertigo * acute pain * walking disability (independent walking distance \<10 meters) * uncontrolled cardiovascular disease (e.g.: uncontrolled blood pressure) * gait problems caused by hip or knee endoprothesis * weakness due to neurological problems * known or suspected non-compliance * contraindications on ethical grounds
optical coherence tomography following paclitaxel eluting stent implantation in multivessel coronary artery disease

Conditions: Coronary Artery Disease

Summary: a prospective optical coherence tomography (oct) study on the completeness of strut coverage and vessel wall response, at different time points (3-6-9 months), following taxus liberte stent implantation (staged procedures) in patients with multi vessel native coronary artery lesions

major concerns were addressed to the delayed healing process of drug-eluting stents in off-label indications. to date no studies have detailed the in-vivo completeness of des coverage at different time points. the objective of this prospective study is to measure the completeness of strut coverage and vessel wall response (neointima disomogeneity, acquired late incomplete strut apposition) at different time points following paclitaxel-eluting stent implantation, in patients with multivessel disease treated with staged pci procedures. optical coherence tomography (oct) that detects smaller degrees of stent strut coverage more accurately than ivus will be used at different time point. intravascular ultrasound (ivus) will be performed as per normal practice at any index procedures and 9 months elective follow-up.

Eligibility criteria:
inclusion criteria: 1. multivessel coronary artery disease (two or 3 vd) to be treated at 2 sequences (staged procedures) with paclitaxel-polymer eluting stents 2. native coronary artery disease with \>= 75% diameter stenosis 3. vessel size in between 2.5 and 3.5 mm. 4. written informed consent signed exclusion criteria: 1. no suitable anatomy for oct scan: (truly ostial , tortuous anatomy, very distal lesions or vessels larger than 3.75 in reference diameter). 2. significant left main coronary artery disease, 3. lesions in bypass grafts, 4. acute myocardial infarction, 5. poor cardiac function as defined by left ventricular ejection fraction ≤ 30%. 6. allergy to aspirin and or clopidogrel/ticlopidine, 7. renal failure with creatinine value \> 2.5 mg/dl

Keywords: drug eluting stents percutaneous coronary interventions optical coherence tomography